Ronald Taylor - Allergan Plc Independent Director
Director
Mr. Ronald R. Taylor was Independent Director of Allergan Plc. He joined the Board of Directors in 1994. Mr. Taylor is currently the President of Tamarack Bay, LLC, a private consulting firm. Prior to forming Tamarack Bay, Mr. Taylor was a general partner of Enterprise Partners VC, a VC firm, from 1998 until 2001. In 1987, Mr. Taylor founded Pyxis Corporationrationration, a manufacturer of automated drug dispensers for hospitals, where he served as Chairman, President, and Chief Executive Officer until its purchase by Cardinal Health, Inc., in 1996. For six years before founding Pyxis, Mr. Taylor was responsible for operations and international sales at Hybritech, Inc., a biotechnology company. Before joining Hybritech, he served for 10 years in management roles at Allergan, Inc. Mr. Taylor currently serves on the Board of Directors of ResMed Inc., where he is the Lead Director and Chair of the Nominating and Governance Committee, and as the Chairman of the Board of Directors of Tillster. since 2013.
| Age | 68 |
| Tenure | 11 years |
| Phone | 862 261 7000 |
| Web | http://www.allergan.com |
Ronald Taylor Latest Insider Activity
Tracking and analyzing the buying and selling activities of Ronald Taylor against Allergan Plc stock is an integral part of due diligence when investing in Allergan Plc. Ronald Taylor insider activity provides valuable insight into whether Allergan Plc is net buyers or sellers over its current business cycle. Note, Allergan Plc insiders must abide by specific rules, including filing SEC forms every time they buy or sell Allergan Plc'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Ronald Taylor over three months ago Acquisition by Ronald Taylor of 1768 shares of ResMed subject to Rule 16b-3 |
Allergan Plc Management Efficiency
The company has Return on Asset of (0.0564) % which means that on every $100 spent on assets, it lost $0.0564. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.0913) %, meaning that it generated no profit with money invested by stockholders. Allergan Plc's management efficiency ratios could be used to measure how well Allergan Plc manages its routine affairs as well as how well it operates its assets and liabilities.The company has 23.08 B in debt with debt to equity (D/E) ratio of 39.4, demonstrating that the company may be unable to create cash to meet all of its financial commitments. Allergan Plc has a current ratio of 0.98, suggesting that it has not enough short term capital to pay financial commitments when the payables are due. Debt can assist Allergan Plc until it has trouble settling it off, either with new capital or with free cash flow. So, Allergan Plc's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Allergan Plc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Allergan to invest in growth at high rates of return. When we think about Allergan Plc's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Lynda Clarizio | CDW Corp | 57 | |
| Lynn Atchison | Q2 Holdings | 58 | |
| Joseph Laird | FactSet Research Systems | 69 | |
| Sheila Jordan | FactSet Research Systems | 56 | |
| Donna Zarcone | CDW Corp | 60 | |
| Lynn Tyson | Q2 Holdings | N/A | |
| Siew Choy | FactSet Research Systems | 54 | |
| Scott Miller | FactSet Research Systems | 46 | |
| Scott Billeadeau | FactSet Research Systems | 58 | |
| Robin Selati | CDW Corp | 49 | |
| James Bell | CDW Corp | 69 | |
| Carl Schaper | Q2 Holdings | 66 | |
| Jeffrey Diehl | Q2 Holdings | 50 | |
| Joseph Swedish | CDW Corp | 66 | |
| Charles Doyle | Q2 Holdings | 84 | |
| Barry Allen | CDW Corp | 69 | |
| Lee Shavel | FactSet Research Systems | 53 | |
| Michael Brown | Q2 Holdings | 44 | |
| Michael Dominguez | CDW Corp | 45 | |
| Glenn Creamer | CDW Corp | 53 | |
| Virginia Addicott | CDW Corp | 54 | |
Management Performance
| Return On Equity | -0.0913 | |||
| Return On Asset | -0.0564 |
Allergan Plc Leadership Team
Elected by the shareholders, the Allergan Plc's board of directors comprises two types of representatives: Allergan Plc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Allergan. The board's role is to monitor Allergan Plc's management team and ensure that shareholders' interests are well served. Allergan Plc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Allergan Plc's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Matthew Walsh, Chief Financial Officer, Executive Vice President | ||
| Robert Bailey, Chief Legal Officer and Corporate Secretary | ||
| Robert Stewart, Executive VP and President of Generic and Global Operations | ||
| Ronald Taylor, Independent Director | ||
| Adriane Brown, Independent Director | ||
| William Meury, Executive Vice President, Chief Commercial Officer | ||
| Brenton Saunders, Chairman of the Board, President, Chief Executive Officer | ||
| Wayne Swanton, Executive Vice President - Global Operations | ||
| Robert Hugin, Independent Director | ||
| Nicholson, Chief R&D Officer | ||
| Christopher Bodine, Independent Director | ||
| Karen Ling, Chief Human Resource Officer, Executive Vice President | ||
| Michael Gallagher, Lead Independent Director | ||
| Paul Bisaro, Executive Chairman | ||
| Thomas Freyman, Independent Director | ||
| Catherine Klema, Lead Independent Director | ||
| James DArecca, Chief Accounting Officer | ||
| Christopher Coughlin, Lead Independent Director | ||
| Nesli Basgoz, Independent Director | ||
| Philippe Schaison, Executive Vice President and President Allergan Medical | ||
| Maria Hilado, CFO and Executive VP | ||
| Joseph Boccuzi, Independent Director | ||
| Patrick OSullivan, Independent Director | ||
| Fred Weiss, Independent Director | ||
| A Bailey, Executive Vice President, Chief Legal Officer and Corporate Secretary | ||
| Alex Kelly, Chief Communications Officer | ||
| CDavid Nicholson, Executive Vice President, Chief R&D Officer | ||
| Carol Davidson, Independent Director | ||
| Michael Greenberg, Independent Director | ||
| Ron Taylor, Independent Director | ||
| Jonathon Kellerman, Executive Vice President Chief Compliance Officer | ||
| Paul Navarre, Executive Vice President and President International Brands | ||
| James Bloem, Independent Director | ||
| Karina Calzadilla, IR Contact Officer | ||
| Peter McDonnell, Independent Director |
Allergan Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Allergan Plc a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0913 | |||
| Return On Asset | -0.0564 | |||
| Profit Margin | (0) % | |||
| Operating Margin | 6.84 % | |||
| Current Valuation | 81.41 B | |||
| Shares Outstanding | 328.1 M | |||
| Shares Owned By Insiders | 0.16 % | |||
| Shares Owned By Institutions | 98.25 % | |||
| Number Of Shares Shorted | 15.01 M | |||
| Price To Earning | 24.00 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Allergan Plc in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Allergan Plc's short interest history, or implied volatility extrapolated from Allergan Plc options trading.
Pair Trading with Allergan Plc
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Allergan Plc position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allergan Plc will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Peabody Energy could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Peabody Energy when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Peabody Energy - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Peabody Energy Corp to buy it.
The correlation of Peabody Energy is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Peabody Energy moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Peabody Energy Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Peabody Energy can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the Allergan Plc information on this page should be used as a complementary analysis to other Allergan Plc's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Other Consideration for investing in Allergan Stock
If you are still planning to invest in Allergan Plc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Allergan Plc's history and understand the potential risks before investing.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |